Lilly Highlights Verzenio (abemaciclib) and Jaypirca (pirtobrutinib) Data at 2023 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announces Verzenio and Jaypirca data to be presented at the 2023 ASCO Annual Meeting, including new analyses from the Phase 3 monarchE trial and updated data from the Phase 1/2 BRUIN trial.
June 02, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Verzenio and Jaypirca data presentation at the 2023 ASCO Annual Meeting may positively impact the company's stock.
The presentation of positive data from the Phase 3 monarchE trial and the Phase 1/2 BRUIN trial at the 2023 ASCO Annual Meeting may increase investor confidence in Eli Lilly's products, potentially leading to a positive impact on the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100